培美替尼在医保范围内吗？

Pemetinib (also known as pemetinib, English trade name: pemazyre) is the world's first targeted drug for cholangiocarcinoma. It was launched in the United States in April 2020 to treat previously treated adult patients with locally advanced or metastatic cholangiocarcinoma who have FGFR2 fusion/rearrangement and are unresectable. Since the FGFR2 gene is almost exclusively found in intrahepatic cholangiocarcinoma, pemetinib is a targeted drug for intrahepatic cholangiocarcinoma. Is it covered by medical insurance?

Unfortunately, pemetinib is not currently on the market in China, and naturally it is no longer covered by medical insurance. If patients need medication, they can currently only purchase pemetinib that is available overseas, and they can only pay for the medication themselves. Patients who need to purchase pemetinib and are unable to go abroad can contact a legal and formal overseas medical service institution in China and sign a guarantee contract. Without leaving home, 100% authentic medicines will be mailed directly to you. For specific information, please contact the Medical Companion Travel Service.

According to data from a study, the intrahepatic cholangiocarcinoma-targeted drug pemetinib can achieve an objective response rate of 35.5% and a disease control rate of 82% in the treatment of patients with cholangiocarcinoma. The median duration of response was 9.1 months, with as many as 63% of patients having a response duration of ≥6 months and 18% of patients with a duration of ≥12 months. It is not difficult to see from these data that the targeted drug pemetinib has a very significant effect on disease control and prognosis improvement of intrahepatic cholangiocarcinoma. The advent of the targeted drug pemetinib is good news for many patients with intrahepatic cholangiocarcinoma. This drug has changed the current treatment status of intrahepatic cholangiocarcinoma and provided doctors and patients with a new diagnosis and treatment plan.

After receiving pemetinib, patients must read the instructions carefully to understand the characteristics and contraindications of the drug. Then take the medicine in accordance with the doctor's instructions and do not take the medicine blindly. The recommended dose of pemetinib is 13.5 mg orally daily for 1 day for 21 days, followed by 7 days off, in a 21-day cycle. Continue treatment until disease progression or unacceptable toxicity. Take pemetinib with or without food at about the same time each day. Swallow tablet whole. Do not crush, chew, split or dissolve tablets. If the patient misses a dose by 4 hours or more, or experiences vomiting, restart the medication with the next scheduled dose.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: